Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $275.00

Revolution Medicines (NASDAQ:RVMD) had its target price increased by Guggenheim from $240.00 to $275.00 in a report issued on Friday morning, Marketbeat reports. They currently have a buy rating on the stock.

Several other brokerages have also weighed in on RVMD. Evercore reiterated an “outperform” rating and set a $320.00 price objective on shares of Revolution Medicines in a report on Thursday. Piper Sandler raised their target price on Revolution Medicines to $172.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Mizuho raised their target price on Revolution Medicines from $185.00 to $215.00 and gave the company an “outperform” rating in a research note on Monday, July 6th. TD Cowen raised Revolution Medicines to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Needham & Company LLC upped their price target on Revolution Medicines from $236.00 to $240.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $198.89.

Revolution Medicines Stock Performance

Shares of RVMD stock opened at $207.88 on Friday. The firm has a 50 day moving average of $193.33 and a 200-day moving average of $148.95. The company has a market cap of $44.56 billion, a price-to-earnings ratio of -23.57 and a beta of 1.39. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. Revolution Medicines has a 52 week low of $37.56 and a 52 week high of $224.31.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the prior year, the business posted ($1.31) EPS. On average, equities analysts forecast that Revolution Medicines will post -8.85 earnings per share for the current year.

Insider Activity

In other news, CFO Jack Anders sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total value of $3,366,600.00. Following the transaction, the chief financial officer owned 123,269 shares in the company, valued at $20,749,870.77. This trade represents a 13.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Sushil Patel sold 5,580 shares of Revolution Medicines stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $187.99, for a total value of $1,048,984.20. Following the transaction, the director directly owned 21,656 shares in the company, valued at approximately $4,071,111.44. The trade was a 20.49% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 212,497 shares of company stock worth $38,206,486. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Revolution Medicines

Several large investors have recently bought and sold shares of RVMD. Contravisory Investment Management Inc. purchased a new stake in shares of Revolution Medicines in the second quarter valued at about $32,000. Global Retirement Partners LLC boosted its holdings in Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after purchasing an additional 361 shares during the last quarter. Torren Management LLC purchased a new position in Revolution Medicines during the fourth quarter worth about $33,000. Johnson Financial Group Inc. purchased a new position in Revolution Medicines during the second quarter worth about $37,000. Finally, Arax Advisory Partners bought a new stake in Revolution Medicines in the 4th quarter worth about $38,000. 94.34% of the stock is currently owned by institutional investors.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.